1
|
Sicinski K, Montanari V, Raman VS, Doyle JR, Harwood BN, Song YC, Fagan MP, Rios M, Haines DR, Kopin AS, Beinborn M, Kumar K. A Non-Perturbative Molecular Grafting Strategy for Stable and Potent Therapeutic Peptide Ligands. ACS Cent Sci 2021; 7:454-466. [PMID: 33791428 PMCID: PMC8006168 DOI: 10.1021/acscentsci.0c01237] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/16/2020] [Indexed: 06/12/2023]
Abstract
The gut-derived incretin hormone, glucagon-like peptide-1 (GLP1), plays an important physiological role in attenuating post-prandial blood glucose excursions in part by amplifying pancreatic insulin secretion. Native GLP1 is rapidly degraded by the serine protease, dipeptidyl peptidase-4 (DPP4); however, enzyme-resistant analogues of this 30-amino-acid peptide provide an effective therapy for type 2 diabetes (T2D) and can curb obesity via complementary functions in the brain. In addition to its medical relevance, the incretin system provides a fertile arena for exploring how to better separate agonist function at cognate receptors versus susceptibility of peptides to DPP4-induced degradation. We have discovered that novel chemical decorations can make GLP1 and its analogues completely DPP4 resistant while fully preserving GLP1 receptor activity. This strategy is also applicable to other therapeutic ligands, namely, glucose-dependent insulinotropic polypeptide (GIP), glucagon, and glucagon-like peptide-2 (GLP2), targeting the secretin family of receptors. The versatility of the approach offers hundreds of active compounds based on any template that target these receptors. These observations should allow for rapid optimization of pharmacological properties and because the appendages are in a position crucial to receptor stimulation, they proffer the possibility of conferring "biased" signaling and in turn minimizing side effects.
Collapse
Affiliation(s)
- Kathleen
M. Sicinski
- Department
of Chemistry, Tufts University, Medford, Massachusetts 02155, United States
| | - Vittorio Montanari
- Department
of Chemistry, Tufts University, Medford, Massachusetts 02155, United States
| | - Venkata S. Raman
- Department
of Chemistry, Tufts University, Medford, Massachusetts 02155, United States
| | - Jamie R. Doyle
- Molecular
Cardiology Research Institute, Tufts Medical
Center, Boston, Massachusetts 02111, United States
| | - Benjamin N. Harwood
- Molecular
Cardiology Research Institute, Tufts Medical
Center, Boston, Massachusetts 02111, United States
| | - Yi Chi Song
- Department
of Chemistry, Tufts University, Medford, Massachusetts 02155, United States
| | - Micaella P. Fagan
- Department
of Neuroscience, Tufts University School
of Medicine, Boston, Massachusetts 02111, United States
| | - Maribel Rios
- Department
of Neuroscience, Tufts University School
of Medicine, Boston, Massachusetts 02111, United States
| | - David R. Haines
- Department of Chemistry, Wellesley College, Wellesley, Massachusetts 02481, United States
| | - Alan S. Kopin
- Molecular
Cardiology Research Institute, Tufts Medical
Center, Boston, Massachusetts 02111, United States
| | - Martin Beinborn
- Department
of Chemistry, Tufts University, Medford, Massachusetts 02155, United States
- Molecular
Cardiology Research Institute, Tufts Medical
Center, Boston, Massachusetts 02111, United States
| | - Krishna Kumar
- Department
of Chemistry, Tufts University, Medford, Massachusetts 02155, United States
| |
Collapse
|
2
|
Pottorf TS, Fagan MP, Burkey BF, Cho DJ, Vath JE, Tran PV. MetAP2 inhibition reduces food intake and body weight in a ciliopathy mouse model of obesity. JCI Insight 2020; 5:134278. [PMID: 31877115 DOI: 10.1172/jci.insight.134278] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2019] [Accepted: 12/18/2019] [Indexed: 12/13/2022] Open
Abstract
The ciliopathies Bardet-Biedl syndrome and Alström syndrome are genetically inherited pleiotropic disorders with hyperphagia and obesity as primary clinical features. Methionine aminopeptidase 2 inhibitors (MetAP2i) have been shown in preclinical and clinical studies to reduce food intake, body weight, and adiposity. Here, we investigated the effects of MetAP2i administration in a mouse model of ciliopathy produced by conditional deletion of the Thm1 gene in adulthood. Thm1 conditional knockout (cko) mice showed decreased hypothalamic proopiomelanocortin expression as well as hyperphagia, obesity, metabolic disease, and hepatic steatosis. In obese Thm1-cko mice, 2-week administration of MetAP2i reduced daily food intake and reduced body weight 17.1% from baseline (vs. 5% reduction for vehicle). This was accompanied by decreased levels of blood glucose, insulin, and leptin. Further, MetAP2i reduced gonadal adipose depots and adipocyte size and improved liver morphology. This is the first report to our knowledge of MetAP2i reducing hyperphagia and body weight and ameliorating metabolic indices in a mouse model of ciliopathy. These results support further investigation of MetAP2 inhibition as a potential therapeutic strategy for ciliary-mediated forms of obesity.
Collapse
Affiliation(s)
- Tana S Pottorf
- Jared Grantham Kidney Institute and.,Department of Anatomy and Cell Biology, University of Kansas Medical Center (KUMC), Kansas City, Kansas, USA
| | | | | | - David J Cho
- Jared Grantham Kidney Institute and.,Department of Anatomy and Cell Biology, University of Kansas Medical Center (KUMC), Kansas City, Kansas, USA
| | | | - Pamela V Tran
- Jared Grantham Kidney Institute and.,Department of Anatomy and Cell Biology, University of Kansas Medical Center (KUMC), Kansas City, Kansas, USA
| |
Collapse
|